Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Myasthenia Gravis 2

Interventions

rozanolixizumab 7zilucoplan 6efgartigimod alfa 5eculizumab 4telitacicept 3ravulizumab 3Tacrolimus 3Rituximab 3Amifampridine 3Prednisone 2Mycophenolic Acid 2HBM9161 2satralizumab 1remibrutinib 1iptacopan 1inebilizumab 1Thymectomy 1Sugars 1Steroids 1Sodium Chloride 1Pyridostigmine Bromide 1Prednisolone 1Plasmapheresis 1Leflunomide 1Immunoglobulins, Intravenous 1Hizentra 1Cladribine 1Azathioprine 1Alkalies 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Myasthenia Gravis × HBM9161 × Clear all
NCT05332210 2026-04-28

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
111 enrolled

Myasthenia Gravis

NCT05039190 2023-03-08

MG

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
132 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡